Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis : a multicentre, open-label, partially randomised, phase 2b trial

Tweed, Connor D.; Dawson, Rodney; Burger, Divan Aristo; Conradie, Almari; Crook, Angela M.; Mendel, Carl M.; Conradie, Francesca; Diacon, Andreas H.; Ntinginya, Nyanda E.; Everitt, Daniel E.; Haraka, Frederick; Li, Mengchum; Van Niekerk, Christo H.; Okwera, Alphonse; Rassool, Mohammed S.; Reither, Klaus; Sebe, Modulakgotla A.; Staples, Suzanne; Variava, Ebrahim; Spigelman, Melvin

dc.contributor.author	Tweed, Connor D.
dc.contributor.author	Dawson, Rodney
dc.contributor.author	Burger, Divan Aristo
dc.contributor.author	Conradie, Almari
dc.contributor.author	Crook, Angela M.
dc.contributor.author	Mendel, Carl M.
dc.contributor.author	Conradie, Francesca
dc.contributor.author	Diacon, Andreas H.
dc.contributor.author	Ntinginya, Nyanda E.
dc.contributor.author	Everitt, Daniel E.
dc.contributor.author	Haraka, Frederick
dc.contributor.author	Li, Mengchum
dc.contributor.author	Van Niekerk, Christo H.
dc.contributor.author	Okwera, Alphonse
dc.contributor.author	Rassool, Mohammed S.
dc.contributor.author	Reither, Klaus
dc.contributor.author	Sebe, Modulakgotla A.
dc.contributor.author	Staples, Suzanne
dc.contributor.author	Variava, Ebrahim
dc.contributor.author	Spigelman, Melvin
dc.date.accessioned	2020-03-10T09:38:38Z
dc.date.available	2020-03-10T09:38:38Z
dc.date.issued	2019-12
dc.description.abstract	Please read abstract in the article.	en_ZA
dc.description.department	Statistics	en_ZA
dc.description.librarian	hj2020	en_ZA
dc.description.sponsorship	TB Alliance, UK Department for International Development, Bill & Melinda Gates Foundation, US Agency for International Development, Directorate General for International Cooperation of the Netherlands, Irish Aid, Australia Department of Foreign Affairs and Trade, and the Federal Ministry for Education and Research of Germany.	en_ZA
dc.description.uri	https://www.thelancet.com/journals/lanres/home	en_ZA
dc.identifier.citation	Tweed, C.D., Dawson, R., Burger, D.A. et al. 2019, 'Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial', Lancet Respiratory Medicine, vol. 7, no. 12, pp. 1048-1058.	en_ZA
dc.identifier.issn	2213-2600 (print)
dc.identifier.issn	2213-2619 (online)
dc.identifier.other	10.1016/S2213-2600(19)30366-2
dc.identifier.uri	http://hdl.handle.net/2263/73699
dc.language.iso	en	en_ZA
dc.publisher	Elsevier	en_ZA
dc.rights	Article is published Open Access.	en_ZA
dc.subject	Tuberculosis (TB)	en_ZA
dc.subject	Bactericidal activity	en_ZA
dc.subject	Safety profile	en_ZA
dc.subject	Pyrazinamide	en_ZA
dc.subject	Bedaquiline (BDQ)	en_ZA
dc.subject	Pretomanid (PA‐824)	en_ZA
dc.subject	Moxifloxacin	en_ZA
dc.subject	Pulmonary tuberculosis	en_ZA
dc.title	Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis : a multicentre, open-label, partially randomised, phase 2b trial	en_ZA
dc.type	Article	en_ZA